Records containing: Pancreatic Ductal Adenocarcinoma (PDAC)

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2026-10-30
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)
CLINICAL_TRIALS study record update · 2026-10-29
M-POP: A Phase Ib/II Open Label Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer
CLINICAL_TRIALS study record update · 2026-10-28
Multimodal EUS and Clinical Feature-Based Radiomics for AI-Assisted Differentiation of Mass-Forming Autoimmune Pancreatitis and Pancreatic Cancer: A Multicenter Ambispective Study
CLINICAL_TRIALS study record update · 2026-10-27
A Phase I/II Study of Dose Escalation, PK Expansion, and Cohort Expansion to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6062 in Patients With Advanced Solid Tumors
CLINICAL_TRIALS study record update · 2026-10-23
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2026-10-22
PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)
CLINICAL_TRIALS study record update · 2026-10-22
Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial
CLINICAL_TRIALS study record update · 2026-10-22
Breath Research Narrow Validation for Gastrointestinal Cancer Detection
CLINICAL_TRIALS study record update · 2026-10-22
Prospective Pan-European Registry of Distal Pancreatectomy With Celiac Axis Resection
CLINICAL_TRIALS study record update · 2026-10-16
A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
CLINICAL_TRIALS study record update · 2026-10-15
A Single-Arm, Multicenter, Open-Label, Phase Ia/Ib Clinical Study of NW-301V in Advanced Solid Tumors Harboring KRAS G12V Mutations
CLINICAL_TRIALS study record update · 2026-10-14
Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors
CLINICAL_TRIALS study record update · 2026-10-13
RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
CLINICAL_TRIALS study record update · 2026-10-13
A Randomized Controlled Study on the Impact of a Specialized Oral Nutritional Supplement on Muscle Mass and Chemotherapy Tolerance in Pancreatic Cancer Patients
CLINICAL_TRIALS study record update · 2026-10-02
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma
CLINICAL_TRIALS study record update · 2026-09-30
Pancreatic Endoscopic Ultrasound-guided RadioFrequency for Inoperable Carcinoma Treatment (PERFECT Study)
CLINICAL_TRIALS study record update · 2026-09-18
Modified FOLFIRINOX and Pentamidine as First-line Treatment in Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
CLINICAL_TRIALS study record update · 2026-09-18
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS.
CLINICAL_TRIALS study record update · 2026-09-18
Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer
CLINICAL_TRIALS study record update · 2026-09-18
A Phase 2 Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
CLINICAL_TRIALS study record update · 2026-09-17
Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
CLINICAL_TRIALS study record update · 2026-09-15
Monitoring Physical Function Changes for Patients Living With Pancreatic Ductal Adenocarcinoma: Potential for Better Understanding of Treatment Trajectory and Survival
CLINICAL_TRIALS study record update · 2026-09-15
A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
CLINICAL_TRIALS study record update · 2026-09-10
A Phase 1 Theranostic Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of SKL35501, an Alpha-Emitting Radiopharmaceutical Targeting NTSR1, With SKL35502 as Companion Imaging Agent in Adult Patients With Selected Advanced Solid Tumors
CLINICAL_TRIALS study record update · 2026-09-04
A Randomized, Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of YL201 Versus Liposomal Irinotecan in Combination With 5-Fluorouracil/Leucovorin in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed Prior Gemcitabine-based Systemic Therapy